Should I buy or sell Lexeo Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lexeo Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LXEO shares. View LXEO analyst ratings or view top-rated stocks .

What is Lexeo Therapeutics' stock price target for 2024?

6 Wall Street research analysts have issued twelve-month price objectives for Lexeo Therapeutics' stock. Their LXEO share price targets range from $19.00 to $23.00. On average, they anticipate the company's share price to reach $20.80 in the next twelve months. This suggests a possible upside of 55.0% from the stock's current price. View analysts price targets for LXEO or view top-rated stocks among Wall Street analysts .

How have LXEO shares performed in 2023?

Lexeo Therapeutics' stock was trading at $10.05 at the beginning of 2023. Since then, LXEO shares have increased by 33.5% and is now trading at $13.42. View the best growth stocks for 2023 here .

When is Lexeo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 11th 2024. View our LXEO earnings forecast .

How were Lexeo Therapeutics' earnings last quarter?

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) released its quarterly earnings results on Monday, December, 11th. The company reported ($12.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.96) by $11.40.

When did Lexeo Therapeutics IPO?

(LXEO) raised $100 million in an initial public offering (IPO) on Friday, November 3rd 2023. The company issued 9,090,910 shares at a price of $11.00 per share.

When did Lexeo Therapeutics' quiet period expire?

Lexeo Therapeutics' quiet period expired on Wednesday, December 13th. Lexeo Therapeutics had issued 9,090,910 shares in its public offering on November 3rd. The total size of the offering was $100,000,010 based on an initial share price of $11.00. During Lexeo Therapeutics' quiet period, underwriters and any insiders involved in the IPO were prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Lexeo Therapeutics?

Shares of LXEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:LXEO

Lexeo Therapeutics (LXEO) Stock Price, News & Analysis

$13.42

-1.13 (-7.77%)

(As of 12/29/2023 ET)

Compare

Today's Range: $12.76
▼
$14.57
50-Day Range: N/A
52-Week Range: $9.00
▼
$17.72

Volume: 63,596 shs
Average Volume: 128,410 shs
Market Capitalization: $357.64 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $20.80

Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Insider Trades SEC Filings Social Media

Lexeo Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 55.0% Upside
$20.80 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.61
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$5 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($4.52) to ($2.56) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.51 out of 5 stars

Medical Sector

162nd out of 950 stocks

Biological Products, Except Diagnostic Industry

23rd out of 158 stocks

4.5

Analyst's Opinion

Consensus Rating
Lexeo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $20.80, Lexeo Therapeutics has a forecasted upside of 55.0% from its current price of $13.42.
Amount of Analyst Coverage
Lexeo Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

N/A

Short Interest

Short Interest
There is no current short interest data available for LXEO.

0.0

Dividend Strength

Dividend Yield
Lexeo Therapeutics does not currently pay a dividend.
Dividend Growth
Lexeo Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LXEO.

3.7

News and Social Media Coverage

News Sentiment
Lexeo Therapeutics has a news sentiment score of 1.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Lexeo Therapeutics this week, compared to 1 article on an average week.
Search Interest
7 people have searched for LXEO on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lexeo Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,999,995.00 in company stock and sold $0.00 in company stock.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Lexeo Therapeutics are expected to grow in the coming year, from ($4.52) to ($2.56) per share.

See Top Rated MarketRank™ Stocks Here

About Lexeo Therapeutics Stock (NASDAQ:LXEO)

Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

LXEO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LXEO Stock News Headlines

December 25, 2023 | americanbankingnews.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Buy" by Brokerages

December 19, 2023 | seekingalpha.com

Lexeo gets orphan drug, fast track status for cardiac gene therapy

December 31, 2023 | MarketBeat Internal (Ad)

New Year's Sale: Get MarketBeat All Access Free For 30 Days

Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Click the link to claim your $300.00 account credit and free 30-day subscription

December 18, 2023 | markets.businessinsider.com

Lexeo Therapeutics Says FDA Grants Fast Track And Orphan Drug Designation To LX2020

December 18, 2023 | finance.yahoo.com

Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

December 14, 2023 | markets.businessinsider.com

Stable Execution and Positive Clinical Progress Support $19 Price Target for Lexeo Therapeutics

December 13, 2023 | finance.yahoo.com

Lexeo Therapeutics Inc (LXEO) Reports Q3 2023 Financial Results and Advances Clinical Programs

December 11, 2023 | finance.yahoo.com

Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights

December 31, 2023 | MarketBeat Internal (Ad)

New Year's Sale: Get MarketBeat All Access Free For 30 Days

December 8, 2023 | morningstar.com

Lexeo Therapeutics Inc LXEO

See More Headlines

Receive LXEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexeo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 12/11/2023
Today: 12/31/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/11/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LXEO
Previous Symbol: NASDAQ:LXEO
CUSIP: N/A
CIK: 1907108
Web: www.lexeotx.com
Phone: 212-547-9879
Fax: N/A
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $20.80
High Stock Price Target: $23.00
Low Stock Price Target: $19.00
Potential Upside/Downside: +55.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 26,650,000
Free Float: N/A
Market Cap: $357.64 million
Optionable: Not Optionable
Beta: N/A

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. R. Nolan Townsend (Age 43)
CEO & Director
Comp: $705.43k
Dr. Paul B. McCormac Ph.D. (Age 53)
Chief Technical Officer
Comp: $471.73k
Ms. Jenny R. Robertson (Age 49)
Chief Legal & Administrative Officer
Comp: $436.13k
Dr. Ronald G. Crystal M.D.
Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board
Dr. Eric Adler M.D. (Age 50)
Chief Scientific Officer
Mr. Micah Zajic (Age 42)
Chief Business Officer
Dr. Jordan Shin M.D.
Ph.D., Senior Vice President of Clinical Development & Translational Science, Cardiology
Dr. Jordan S. Dubow M.D. (Age 45)
Head of CNS Clinical Development
Dr. Sandi See Tai M.D.
Senior Vice President of Clinical Development & Operations
Mr. Ryan McHenry
VP & Corporate Controller

Key Competitors

View All Competitors

Insiders

Fund Vi L.P. Omega
Bought 454,545 shares on 11/7/2023
Total: $5.00 M ($11.00/share)

View All Insider Transactions

LXEO Stock Analysis - Frequently Asked Questions

Should I buy or sell Lexeo Therapeutics stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lexeo Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LXEO shares.
View LXEO analyst ratings or view top-rated stocks.
What is Lexeo Therapeutics' stock price target for 2024?: 6 Wall Street research analysts have issued twelve-month price objectives for Lexeo Therapeutics' stock. Their LXEO share price targets range from $19.00 to $23.00. On average, they anticipate the company's share price to reach $20.80 in the next twelve months. This suggests a possible upside of 55.0% from the stock's current price.
View analysts price targets for LXEO or view top-rated stocks among Wall Street analysts.
How have LXEO shares performed in 2023?: Lexeo Therapeutics' stock was trading at $10.05 at the beginning of 2023. Since then, LXEO shares have increased by 33.5% and is now trading at $13.42.
View the best growth stocks for 2023 here.
When is Lexeo Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 11th 2024.
View our LXEO earnings forecast.

How were Lexeo Therapeutics' earnings last quarter?: Lexeo Therapeutics, Inc. (NASDAQ:LXEO) released its quarterly earnings results on Monday, December, 11th. The company reported ($12.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.96) by $11.40.
When did Lexeo Therapeutics IPO?: (LXEO) raised $100 million in an initial public offering (IPO) on Friday, November 3rd 2023. The company issued 9,090,910 shares at a price of $11.00 per share.
When did Lexeo Therapeutics' quiet period expire?: Lexeo Therapeutics' quiet period expired on Wednesday, December 13th. Lexeo Therapeutics had issued 9,090,910 shares in its public offering on November 3rd. The total size of the offering was $100,000,010 based on an initial share price of $11.00. During Lexeo Therapeutics' quiet period, underwriters and any insiders involved in the IPO were prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.
How do I buy shares of Lexeo Therapeutics?: Shares of LXEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LXEO) was last updated on 12/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Lexeo Therapeutics (LXEO) Stock Price, News & Analysis